Smartwatch measures blood oxygen with sensors and algorithms
A new smartwatch can measure oxygen levels in the blood, thanks to a sensor capturing biometric rhythms through the skin.
LifeQ's new smartwatch uses reflected light from a sensor embedded in the back, capable of measuring blood oxygen levels either continuosly or through tests initiated by the wearer. Continuous measuring could be beneficial for people who require monitoring through the night, for instance people with sleep apnea who can experience sudden drops in oxygen while they sleep.
The Xiaomi Mi smartwatch uses technology produced by Chinese multinational electronics company Xiaomi. The sensor has been designed by LifeQ in partnership with Texas Instruments, and it allows the device to capture four separate optical paths through the skin. These multiple paths allow the algorithms on the device to isolate biometric signals from environmental noise, to deliver an accurate result while limiting power consumption of the sensor.
Its design uses multiple diodes, wavelengths and a chip made by Texas Instruments to deliver further improvements over the lifetime of the device.
The release of the smartwatch follows LifeQ’s Covid-19 tracking system for the workplace. The Atlanta-based startup has also released a fitbit, among other devices that can measure biometrics and other health information.
“The incorporation of our blood oxygen measurement capabilities into the Xiaomi Mi Smart Watch is the culmination of years of research working with leading device, silicon and sensor partners across the globe” Laurie Olivier, CEO of LifeQ, said.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”